Payload Information

General Information of This Payload

Payload ID	PAY0DWLYN
Name	Glucocorticoid receptor modulator
Synonyms	Glucocorticoid receptor modulator Click to Show/Hide
Target(s)	Glucocorticoid receptor (NR3C1)			Target Info
Structure
Structure	3D MOL		2D MOL
Formula	C35H40NO9P
Isosmiles	CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CC1OC(c3ccc(Cc4cccc(N)c4)cc3)OC12C(=O)COP(=O)(O)O
InChI	InChI=1S/C35H40NO9P/c1-33-13-12-25(37)16-23(33)10-11-26-27-17-30-35(29(39)19-43-46(40,41)42,34(27,2)18-28(38)31(26)33)45-32(44-30)22-8-6-20(7-9-22)14-21-4-3-5-24(36)15-21/h3-9,12-13,15-16,26-28,30-32,38H,10-11,14,17-19,36H2,1-2H3,(H2,40,41,42)
InChIKey	HIJXVAAACYBVOP-UHFFFAOYSA-N
Pharmaceutical Properties	Molecule Weight	649.677	Polar area	165.61
	Complexity	46	xlogp Value	4.5794
	Heavy Count	46	Rot Bonds	7
	Hbond acc	8	Hbond Donor	4

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

ABBV-154 [Phase 2]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT05068284	Phase Status	Phase 2
Clinical Description	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active crohn's disease (CD): aim-cd.
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT04972968	Phase Status	Phase 2
Clinical Description	A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of ABBV-154 in subjects with polymyalgia rheumatica (PMR) dependent on glucocorticoid treatment.
Experiment 3 Reporting the Activity Date of This ADC				[3]
*Related Clinical Trial*
NCT Number	NCT04888585	Phase Status	Phase 2
Clinical Description	A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active rheumatoid arthritis with inadequate response to biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsdmards).
Experiment 4 Reporting the Activity Date of This ADC				[4]
*Related Clinical Trial*
NCT Number	NCT05556226	Phase Status	Phase 1
Clinical Description	A phase 1 study in healthy subjects to evaluate the relative bioavailability of ABBV-154.

References

Ref 1	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD, NCT05068284
Ref 2	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, NCT04972968
Ref 3	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs), NCT04888585
Ref 4	A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of ABBV-154, NCT05556226